-
公开(公告)号：WO2021174113A1
公开(公告)日：2021-09-02
申请号：PCT/US2021/020074
申请日：2021-02-26
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： ANDREEV, Julian , PEREZ BAY, Andres , DALY, Christopher , DELFINO, Frank , HAN, Amy , NITTOLI, Thomas , OLSON, William , THURSTON, Gavin
Abstract: Provided herein are bispecific antigen-binding molecules that bind HER2 and methods of use thereof. The bispecific antigen-binding molecules comprise a first and a second antigen-binding domain, wherein the first and second antigen-binding domains bind to two different (preferably non-overlapping) epitopes of the extracellular domain of human HER2. The bispecific antigen-binding molecules cluster on the surface of HER2 IHC2+ and IHC3+ cells, and are internalized into the cellular lysosomes. Also included are antibody-drug conjugates (ADCs) comprising the antibodies or bispecific antigen-binding molecules provided herein linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treating cancer in a subject by administering to the subject a bispecific antigen-binding molecule or an ADC thereof.
-
2.发明申请USE OF ANGIOPOIETINS IN PROMOTING BLOOD COAGULATION AND IN THE TREATMENT OF BLOOD COAGULATION DISORDERS 审中-公开使用血管生成促进血液凝结和治疗血液凝结异常
公开(公告)号：WO2017079556A1
公开(公告)日：2017-05-11
申请号：PCT/US2016/060527
申请日：2016-11-04
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： DALY, Christopher , DAVIS, Samuel
CPC classification number: A61K38/1891 , C07K14/515 , C07K2319/30
Abstract: The present invention provides methods for promoting blood coagulation and/or treating blood coagulation disorders in a subject in need thereof. The methods of the present invention comprise administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising an angiopoietin protein or a modified angiopoietin protein molecule such as AngF1 -Fc-F1 or AngF2-Fc-F2.
Abstract translation: 本发明提供了在需要其的受试者中促进凝血和/或治疗凝血障碍的方法。 本发明的方法包括向有需要的受试者施用治疗有效量的包含血管生成素蛋白或修饰的血管生成素蛋白分子例如AngF1-Fc-F1或AngF2-Fc-F2的药物组合物。
-
公开(公告)号：WO2013048883A2
公开(公告)日：2013-04-04
申请号：PCT/US2012/056446
申请日：2012-09-21
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： DALY, Christopher , MACDONALD, Douglas , DUAN, Xunbao
IPC: C07K16/32 , A61K39/395
CPC classification number: A61K39/39558 , A61K31/517 , A61K31/5377 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K16/2863 , C07K16/3023 , C07K16/3046 , C07K16/3053 , C07K16/32 , C07K16/40 , C07K2317/21 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/77 , C07K2317/92
Abstract: The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand such as neuregulin 1. The antibodies of the invention are useful for the treatment of various cancers.
Abstract translation: 本发明提供了与ErbB3结合的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人ErbB3结合的完全人抗体。 在某些实施方案中，本发明的抗体阻断ErbB3与ErbB3配体如神经调节蛋白1的相互作用。本发明的抗体可用于治疗各种癌症。
-
Patent Agency Ranking4.发明申请METHODS FOR REDUCING OR PREVENTING GROWTH OF TUMORS RESISTANT TO EGFR AND/OR ERBB3 BLOCKADE 审中-公开减少或预防抗EGFR和/或ERBB3阻断肿瘤生长的方法
公开(公告)号：WO2017100642A1
公开(公告)日：2017-06-15
申请号：PCT/US2016/065925
申请日：2016-12-09
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： DALY, Christopher , CASTANARO, Carla , ZHANG, Wen , THURSTON, Gavin
CPC classification number: C07K16/2863 , A61K31/00 , A61K2039/507 , C07K16/32
Abstract: The present invention provides methods for inhibiting or attenuating the growth of a tumor that is resistant to a blockade of EGFR, which include administering an EGFR inhibitor, an EGFR inhibitor and a FGFR inhibitor, or an EGFR inhibitor, an FGFR inhibitor and an ErbB3 inhibitor to a subject having a tumor that is or may become resistant to the blockade of EGFR. Blockade of EGFR, FGFR and/or ErbB3 may be effectuated using target specific antibodies or fragments thereof, small molecule tyrosine kinase inhibitors or a combination thereof.
Abstract translation: 本发明提供了抑制或减弱对EGFR阻断有抵抗性的肿瘤生长的方法，其包括施用EGFR抑制剂，EGFR抑制剂和FGFR抑制剂或EGFR抑制剂 ，FGFR抑制剂和ErbB3抑制剂给患有对EGFR阻断或可能变得有抵抗性的肿瘤的受试者。 使用靶特异性抗体或其片段，小分子酪氨酸激酶抑制剂或其组合，可以阻断EGFR，FGFR和/或ErbB3。
-
公开(公告)号：WO2011014469A1
公开(公告)日：2011-02-03
申请号：PCT/US2010/043295
申请日：2010-07-27
Applicant: REGENERON PHARMACEUTICALS, INC. , THURSTON, Gavin , DALY, Christopher
Inventor： THURSTON, Gavin , DALY, Christopher
IPC: C07K16/22 , A61K39/395 , A61P35/00
CPC classification number: C07K16/22 , A61K31/513 , A61K38/1866 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/21 , C07K2317/33 , C07K2317/34 , C07K2317/565 , C07K2317/73 , C07K2317/732 , C07K2317/76 , C07K2317/92 , A61K2300/00
Abstract: The present invention provides antibodies that bind to angiopoietin-2 (Ang-2) and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human Ang-2. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more Ang-2 biological activities including angiogenesis.
Abstract translation: 本发明提供了结合血管生成素-2（Ang-2）的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人Ang-2结合的完全人抗体。 本发明的抗体尤其用于治疗与一种或多种Ang-2生物学活性（包括血管生成）相关的疾病和病症。
-
公开(公告)号：WO2022087243A1
公开(公告)日：2022-04-28
申请号：PCT/US2021/056018
申请日：2021-10-21
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： DALY, Christopher , DELFINO, Frank , HAN, Amy , NITTOLI, Thomas , ZHANG, Li
Abstract: Provided herein are monoclonal antibodies, and antigen-binding fragments thereof, that bind fibroblast growth factor receptor 2 (FGFR2), and methods of use thereof and methods of use thereof. Also included are antibody-drug conjugates (ADCs) comprising the anti-FGFR2 antibodies or antigen-binding fragments thereof linked to a cytotoxic agent, radionuclide, or other moiety, as well as methods of treatment using the same.
-
公开(公告)号：WO2021178556A1
公开(公告)日：2021-09-10
申请号：PCT/US2021/020697
申请日：2021-03-03
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： YOUNG, Tara , DALY, Christopher , THURSTON, Gavin
IPC: C12N15/113
Abstract: Provided herein are methods and compositions related to the treatment or prevention of cancer (e.g, by targeting a tumor in a subject with cancer) by administering to a subject an agent that inhibits autophagy. In certain aspects, provided herein are methods of compositions related to methods of sensitizing cancer cells to tumor necrosis factor-alpha (TNF-α) mediated killing by contacting the cells or administering the agent that inhibits autophagy.
-
公开(公告)号：WO2014004427A3
公开(公告)日：2014-01-03
申请号：PCT/US2013/047476
申请日：2013-06-25
Applicant: REGENERON PHARMACEUTICALS, INC.
Inventor： DALY, Christopher , THURSTON, Gavin , PADADOPOULOS, Nicholas, J.
IPC: C07K16/28
Abstract: The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.014 seconds)
